Linezolid in the treatment of Gram-positive prosthetic joint infections (Q34393206)

1 August 2017

Linezolid in the treatment of Gram-positive prosthetic joint infections (English)

1 reference

1 August 2017

gram-positive bacteria

0 references

1 reference

1

Matteo Bassetti

1 reference

1 August 2017

Francesco Vitale

2

1 reference

1 August 2017

Giovanna Melica

3

1 reference

1 August 2017

Elda Righi

4

1 reference

1 August 2017

Antonio Di Biagio

5

1 reference

1 August 2017

Luigi Molfetta

6

1 reference

1 August 2017

Francesco Pipino

7

1 reference

1 August 2017

Mario Cruciani

8

1 reference

1 August 2017

Dante Bassetti

9

1 reference

1 August 2017

language of work or name

English

0 references

publication date

10 February 2005

1 reference

Journal of Antimicrobial Chemotherapy

1 August 2017

4

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

1 August 2017

55

1 reference

1 August 2017

3

1 reference

1 August 2017

387-390

1 reference

Linezolid penetration into bone and joint tissues infected with methicillin-resistant staphylococci

1 August 2017

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI016

Linezolid penetration into osteo-articular tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI016

Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI016

Linezolid treatment of prosthetic hip Infections due to methicillin-resistant Staphylococcus aureus (MRSA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI016

Linezolid treatment of total prosthetic knee infection due to methicillin-resistant Staphylococcus epidermidis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI016

Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI016

Antibiotic treatment of gram-positive bone and joint infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI016

Treatment of bone, joint, and vascular-access-associated gram-positive bacterial infections with teicoplanin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI016

Linezolid compared with teicoplanin for the treatment of suspected or proven Gram-positive infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI016

Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: a randomized, double-blind, multicentre study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI016

An economic evaluation of a European cohort from a multinational trial of linezolid versus teicoplanin in serious Gram-positive bacterial infections: the importance of treatment setting in evaluating treatment effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI016

Hematologic effects of linezolid: summary of clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI016

Linezolid-associated toxic optic neuropathy: a report of 2 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI016

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI016

21 January 2018

Identifiers

DOI

10.1093/JAC/DKI016

1 reference

1 August 2017

1 reference